Univariate relative risk analyses for survival, relapse, composite relapse or death, and aGVHD in low DC group
Outcome . | RR . | 95% CI . | P . |
|---|---|---|---|
| Death | |||
| All | 3.67 | 1.50-8.94 | .0023 |
| PBSCT | 3.06 | 1.26-7.47 | .0097 |
| Myeloablative | 3.93 | 1.28-12.09 | .0100 |
| Nonmyeloablative | 4.61 | 0.76-27.94 | .0766 |
| Relapse | |||
| All | 5.07 | 1.62-15.89 | .0021 |
| PBSCT | 4.19 | 1.34-13.12 | .0078 |
| Myeloablative | 11.89 | 1.50-94.57 | .0031 |
| Nonmyeloablative | 3.49 | 0.68-17.85 | .1116 |
| Relapse or death | |||
| All | 3.40 | 1.52-7.64 | .0017 |
| PBSCT | 2.80 | 1.25-6.29 | .0093 |
| Myeloablative | 4.80 | 1.57-14.72 | .0284 |
| Nonmyeloablative | 3.37 | 0.82-13.82 | .0745 |
| aGVHD | |||
| All | 3.21 | 1.61-6.40 | .0005 |
| PBSCT | 2.86 | 1.41-5.79 | .0024 |
| Myeloablative | 2.75 | 1.24-6.13 | .0096 |
| Nonmyeloablative | 3.66 | 0.89-14.97 | .0540 |
Outcome . | RR . | 95% CI . | P . |
|---|---|---|---|
| Death | |||
| All | 3.67 | 1.50-8.94 | .0023 |
| PBSCT | 3.06 | 1.26-7.47 | .0097 |
| Myeloablative | 3.93 | 1.28-12.09 | .0100 |
| Nonmyeloablative | 4.61 | 0.76-27.94 | .0766 |
| Relapse | |||
| All | 5.07 | 1.62-15.89 | .0021 |
| PBSCT | 4.19 | 1.34-13.12 | .0078 |
| Myeloablative | 11.89 | 1.50-94.57 | .0031 |
| Nonmyeloablative | 3.49 | 0.68-17.85 | .1116 |
| Relapse or death | |||
| All | 3.40 | 1.52-7.64 | .0017 |
| PBSCT | 2.80 | 1.25-6.29 | .0093 |
| Myeloablative | 4.80 | 1.57-14.72 | .0284 |
| Nonmyeloablative | 3.37 | 0.82-13.82 | .0745 |
| aGVHD | |||
| All | 3.21 | 1.61-6.40 | .0005 |
| PBSCT | 2.86 | 1.41-5.79 | .0024 |
| Myeloablative | 2.75 | 1.24-6.13 | .0096 |
| Nonmyeloablative | 3.66 | 0.89-14.97 | .0540 |